All studies
Endocrinology · EHR · United Kingdom

Wang 2026

Type 2 diabetes

ITT and as-treatedSuperiorityAcademia, Industry2/5 disclosures
Comparisons
3
In the analysis
1
2 withheld
Target trials
1
Emulations reported
3
2 treatments

Comparisons

3 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
Major adverse cardiovascular events
vs DEVOTE·HR·Efficacy
0.910.78–1.06
1.070.63–1.58
overlapClose alignment0.66 SE apart
Major adverse cardiovascular events
vs DEVOTE·HR·Efficacy
0.910.78–1.06
1.360.83–1.86
not pooledPartial alignment
Major adverse cardiovascular events
vs DEVOTE·HR·Efficacy
0.910.78–1.06
2.190.30–3.83
not pooledMajor deviation

Design and methods

Estimand
ITT and as-treated
Design hypothesis
Superiority
Matching / weighting
Propensity-score weighting
Analysis method
Weighted Cox proportional hazards model
Missing data
Multiple imputation
DAG
No
QBA
No

Data and sample

Data type
EHR
Data sources
CPRD linked to hospital data
Geography
United Kingdom
Eligible sample
10430
Treated
812
Control
9618
Emulations
3
Treatments compared
2

Transparency

2/5
Protocol
No pre-registration
Preprint
No preprint
Data availability
Unavailable
Code availability
Unavailable
Conflicts of interest
Declared: Industry
COI institutions
Amgen and other disclosed relationships
Funding
Declared: Public
Funders
Canadian Institutes of Health Research; Fonds de recherche du Québec

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2026_Wang_DEVOTE
DOI
https://doi.org/10.1002/pds.70313
Affiliations
McGill University and collaborating Canadian and UK institutions
Sector
Academia, Industry
Target trials (study level)
DEVOTE
Registration
NCT01959529